Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 7, 2003. The report is a notification of changes in directors' interests in the company's Ordinary Shares, specifically relating to the GlaxoSmithKline US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on shareholding changes within a specific employee retirement fund.
Material Changes
- Shareholding Decrease: The number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan decreased from 18,296,820 to 18,240,658.
- Transaction Details: The reduction occurred on February 6, 2003, due to movement in the fund, with an average price of $36.66 per share.
- Director Interests: Directors Dr. J.P. Garnier and Mr. J.D. Coombe hold interests in the shares held by the fund in the same capacity as other employees or former employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The report is a routine disclosure of director share interests.
Key Facts for Investor Verification
- Verify the total number of ADRs held by the US Retirement Savings Plan post-transaction (18,240,658).
- Confirm the average transaction price of $36.66 for the shares sold on February 6, 2003.
- Note that the change in holdings was driven by fund movements rather than direct sales by the named directors.